Trials / Completed
CompletedNCT00446069
A Efficacy and Safety Trial of Controlled Release (CR) Morphine in Cancer Patients
A Double-blind, Randomized, 2-way Cross-over, Phase II, Efficacy Trial in Cancer Patients to Assess the Overall Efficacy, Patient Preference, Morphine Related Side Effect Profile and Safety of the Egalet® Controlled Release Morphine Formulation 30-240 mg Once Daily Compared to MST Continus® 15-120 mg Twice Daily After 2 Weeks of Treatment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Egalet Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine the effect of Egalet® Morphine once daily compared to MST Continus twice daily on pain intensity and use of rescue medication for break through pain after 2 weeks of treatment in patients with pain due to cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Morphine Sulphate | Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2008-06-01
- Completion
- 2008-08-01
- First posted
- 2007-03-12
- Last updated
- 2016-08-29
Locations
8 sites across 2 countries: Lithuania, Poland
Source: ClinicalTrials.gov record NCT00446069. Inclusion in this directory is not an endorsement.